Metabolic & Obesity CRO

Clinical Development Support for Metabolic and Endocrine Diseases

Guided by a science-first approach, Lotus brings efficiency and experience to your clinical development programs. As a specialized CRO with a focus on metabolic and endocrine clinical research—including Obesity—our experts across the medical, operational, site, and support functions ensure your studies—from early through later phases—are prioritized and streamlined.

0 +

Studies Conducted

0 +

Metabolic Studies Conducted

Obesity Studies Conducted

Note: Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites

Let us put our experience in metabolic and endocrine clinical development to work for you.

The Lotus Difference in Metabolic and Endocrine Clinical Development

Faster Site Activation

With priority access to Evolution Research Group’s (ERG) highly sought-after, US-based sites, we can accelerate study startup with unparalleled operational efficiencies.

130,000+ participant profiles

Our in-house team actively refreshes and recruits from our expanding database of overweight and obese individuals. Our “Every Body Research” initiative provides a rich database of volunteers and patients to jump-start your trial.

Industry-leading Experts

Known for our scientific rigor, our Scientific Leadership Team (SLT) includes some of the industry’s leading experts in obesity and metabolic research.

Early Phase

Derisking an early phase product is a critical first step. Our experts can support proof of concept, proof of mechanism, and specialized testing in our Phase 1 Clinical Pharmacology Units.

Learn More +

FNIH Biomarkers Consortium

With membership in the FNIH Biomarkers Consortium and representation on the Metabolic Diseases Steering Committee, our subject matter experts are at the forefront of supporting these crucial development programs.

Obesity Task Force

This multi-disciplinary team from Lotus and ERG integrates scientific, medical, and operational expertise, including patient access. These metabolic experts are actively involved in guiding your study throughout its duration.

Learn More +

Multi-Site Case Study: The FNIH NIMBLE Stage 2 Project

Lotus was selected to execute the FNIH NIMBLE Stage 2 project—a high-impact study designed to advance noninvasive biomarkers for assessing liver disease progression and therapeutic response in complex metabolic trials. This multi-site effort, conducted solely within ERG’s clinical research network, showcases our ability to deliver integrated, multi-site clinical research initiatives with rigorous data quality and operational excellence, and underscores our capacity to execute specialized, large-scale metabolic studies.

With science always at the forefront, our metabolic experts remain part of the project team throughout the study’s duration.

A Deeper Dive into Early Phase Clinical Development for Metabolic Research

Our dedicated Phase I Units offer over 400 beds and 20+ years of experience involving healthy volunteers and special populations. Our experience spans a broad range of clinical pharmacology studies including:

Advanced Testing Methods

Many of these studies have required overnight stays of up to 60 days and have incorporated advanced testing methods including:

A Deeper Dive into Obesity Drug Development

The unprecedented success of modern obesity treatments is spawning a robust pipeline for weight-loss drugs and a growing opportunity to innovate within this segment. At Lotus and ERG—through our Obesity Task Force—we work collaboratively to anticipate challenges, optimize processes, and uphold the highest standards of compliance and safety. This robust framework and dedicated team ensure we deliver high-quality, impactful clinical research.

“The Obesity Task Force is like compiling an all-star team of experts in Obesity drug development. It gives Sponsors a huge advantage as we look cross-functionally at each study to ensure the protocol design, recruitment strategy, and regulatory landscape align to drive success. And it’s not a one-and-done. We’re reviewing each study every week—our approach is hands-on and collaborative.”

Bill Martin PhD

President, Lotus Clinical Research

Composed of experts across therapeutic and operational domains, the task force integrates cutting-edge science, specialized medical oversight, and operational excellence to ensure the comprehensive success of obesity research projects. By fostering collaboration with thought leaders and industry stakeholders, we aim to shape the future of obesity drug development. By integrating clinical expertise with operational innovation, we remain agile and responsive to the rapidly evolving anti-obesity drug landscape.